UroStream

At #EAU25, Dr. Rodrigo Ledezma and colleagues presented the first-in-human results from the ASTRA study, evaluating robotic-assisted Holmium Laser Enucleation of the Prostate (RoLEP) using the Beacon Platform.This novel robotic…

At EAU25, Dr. Francesco Pellegrino from IRCCS San Raffaele Scientific Institute presented a crucial analysis on the generalizability of randomized trials in newly diagnosed metastatic prostate cancer (mPCa). Using the…

Presented by Dr. Kari Tikkinen and team at EAU25, the APPEAL trial is the largest randomized controlled study to date evaluating the role of antimicrobial prophylaxis during shock wave lithotripsy…

Presented by Dr. Trinity Bivalacqua at EAU25, the BOND-003 Phase 3 trial showcases updated data on intravesical cretostimogene grenadenorepvec, an innovative oncolytic immunotherapy for patients with high-risk BCG-unresponsive non–muscle invasive…

At #EAU25, Dr. Lotte Zuur from the The Netherlands Cancer Institute presented the first results of the PROQURE-I study, a phase I trial evaluating the addition of [¹⁷⁷Lu]Lu-PSMA-617 to standard…

At hashtag#EAU25, André Deschamps presented the results of the Europa Uomo Patient REported Shared decision making Study (EU-PRESS), shedding light on the link between perceived shared decision-making (SDM) and decision…

At the EAU25 Congress, Dr. Sarah Psutka MD MSc shared promising data from the SunRISe-4 trial evaluating neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer (MIBC) who are…

At #EAU25, Dr. Yannic Volz (Ludwig-Maximilians-Universität München) introduced early insights from the ongoing PRACTICE trial (NCT06806059), a randomized, single-blinded study assessing the impact of structured physical activity before radical cystectomy…

At #EAU25, Dr. Vera R. and colleagues from Erasmus MC presented the first study to assess the environmental impact and staff requirements of radical cystectomy (RC) versus chemoradiation (CRT) for…

At #EAU25, Dr. Seth Lerner (Baylor College of Medicine) presented early findings from a Phase 1 study (NCT05483868) evaluating Bel-sar (AU-011)—a novel virus-like drug conjugate (VDC) for non-muscle invasive bladder…